Tackling barriers to COVID-19 vaccine uptake in London: a mixed-methods evaluation.


Journal

Journal of public health (Oxford, England)
ISSN: 1741-3850
Titre abrégé: J Public Health (Oxf)
Pays: England
ID NLM: 101188638

Informations de publication

Date de publication:
14 Jun 2023
Historique:
received: 26 01 2022
medline: 19 6 2023
pubmed: 5 4 2022
entrez: 4 4 2022
Statut: ppublish

Résumé

In response to the COVID-19 pandemic, the first vaccine was administered in December 2020 in England. However, vaccination uptake has historically been lower in London than in other English regions. Mixed-methods: This comprised an analysis of cumulative percentage uptake across London between 8 December 2020 and 6 June 2021 by vaccine priority cohorts and ethnicity. We also undertook thematic analyses of uptake barriers, interventions to tackle these and key learning from a qualitative survey of 27 London local authority representatives, vaccine plans from London's five Integrated Care Systems and interviews with 38 London system representatives. Vaccine uptake was lower in Black ethnic (57-65% uptake) compared with the White British group (90% uptake). Trust was a critical issue, including mistrust in the vaccine itself and in authorities administering or promoting it. The balance between putative costs and benefits of vaccination created uptake barriers for zero-hour and shift workers. Intensive, targeted and 'hyper-local' initiatives, which sustained community relationships and were not constrained by administrative boundaries, helped tackle these barriers. The success of the national vaccination programme depended on conceding local autonomy, investing in responsive and long-term partnerships to engender trust through in-depth understanding of communities' beliefs.

Sections du résumé

BACKGROUND BACKGROUND
In response to the COVID-19 pandemic, the first vaccine was administered in December 2020 in England. However, vaccination uptake has historically been lower in London than in other English regions.
METHODS METHODS
Mixed-methods: This comprised an analysis of cumulative percentage uptake across London between 8 December 2020 and 6 June 2021 by vaccine priority cohorts and ethnicity. We also undertook thematic analyses of uptake barriers, interventions to tackle these and key learning from a qualitative survey of 27 London local authority representatives, vaccine plans from London's five Integrated Care Systems and interviews with 38 London system representatives.
RESULTS RESULTS
Vaccine uptake was lower in Black ethnic (57-65% uptake) compared with the White British group (90% uptake). Trust was a critical issue, including mistrust in the vaccine itself and in authorities administering or promoting it. The balance between putative costs and benefits of vaccination created uptake barriers for zero-hour and shift workers. Intensive, targeted and 'hyper-local' initiatives, which sustained community relationships and were not constrained by administrative boundaries, helped tackle these barriers.
CONCLUSIONS CONCLUSIONS
The success of the national vaccination programme depended on conceding local autonomy, investing in responsive and long-term partnerships to engender trust through in-depth understanding of communities' beliefs.

Identifiants

pubmed: 35373295
pii: 6562974
doi: 10.1093/pubmed/fdac038
pmc: PMC8992332
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-401

Subventions

Organisme : NIH HHS
ID : NIHR20092
Pays : United States
Organisme : NIH HHS
ID : NIHR20092
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Faculty of Public Health.

Références

BMJ Open. 2021 Jul 23;11(7):e053402
pubmed: 34301672
Vaccines (Basel). 2021 Oct 01;9(10):
pubmed: 34696228
Psychol Med. 2022 Oct;52(14):3127-3141
pubmed: 33305716
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
BMJ. 2009 Jun 16;338:b2025
pubmed: 19531549
BJGP Open. 2021 Aug 24;5(4):
pubmed: 34006529

Auteurs

Kristoffer Halvorsrud (K)

Department of Applied Health Research, University College London (UCL), London WC1E 7HB, UK.

Jenny Shand (J)

UCLPartners, London W1T 7HA, UK.
Department of Clinical, Education & Health Psychology, UCL, London WC1E 6BT, UK.

Leonora G Weil (LG)

UK Health Security Agency, London SE1 8UG, UK.

Andrew Hutchings (A)

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Ana Zuriaga (A)

UK Health Security Agency, London SE1 8UG, UK.

Dane Satterthwaite (D)

NHS England and NHS Improvement London, London SE1 6LH, UK.

Jennifer L Y Yip (JLY)

Office for Health Improvement and Disparities, London region, London SW1H 0EU, UK.

Cyril Eshareturi (C)

Public Health England London, London SE1 8UG, UK.

Julie Billett (J)

Office for Health Improvement and Disparities, London region, London SW1H 0EU, UK.

Ann Hepworth (A)

NHS England and NHS Improvement London, London SE1 6LH, UK.

Rakesh Dodhia (R)

NHS England London Shared Service, London SE1 6LH, UK.

Ellen C Schwartz (EC)

Association of Directors of Public Health, London EC4Y 0HA, UK.

Rachel Penniston (R)

UCLPartners, London W1T 7HA, UK.

Emma Mordaunt (E)

UCLPartners, London W1T 7HA, UK.

Sophie Bulmer (S)

UCLPartners, London W1T 7HA, UK.

Helen Barratt (H)

Department of Applied Health Research, University College London (UCL), London WC1E 7HB, UK.

John Illingworth (J)

UCLPartners, London W1T 7HA, UK.

Joanna Inskip (J)

Office for Health Improvement and Disparities, London region, London SW1H 0EU, UK.

Fran Bury (F)

NHS England and NHS Improvement London, London SE1 6LH, UK.

Deborah Jenkins (D)

Royal Free London NHS Foundation Trust, London NW3 2QG, UK.

Sandra Mounier-Jack (S)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Rosalind Raine (R)

Department of Applied Health Research, University College London (UCL), London WC1E 7HB, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH